AOD-9604 vs L-Carnitine (Levocarnitine)

AOD-9604

AOD-9604 is a synthetic peptide based on the C-terminal segment of human growth hormone, with a tyrosine at its N-terminus and a disulfide bond. It was designed to test the idea that this short region carries some of growth hormone's activity on fat metabolism separately from the rest of the molecule. Work on it began with rodent studies of fat cells and whole-animal lipid metabolism, and the peptide later entered human clinical trials, whose published record is sparse. A smaller body of animal work has looked at cartilage in joint injury models. Unlike full-length growth hormone, it is not regarded as a growth hormone receptor agonist, which shapes how its reported activity is interpreted.

L-Carnitine (Levocarnitine)

L-carnitine is a small quaternary ammonium compound made in the liver and kidney from the amino acids lysine and methionine. It is not a peptide, and only the L-stereoisomer is recognised by the enzymes and transporters that handle carnitine. Most carnitine in the diet comes from meat and dairy foods, and the great majority of the body's store is held in skeletal and cardiac muscle. Its biochemistry has been worked out in detail, and there is a large human research literature, including work on inherited disorders of carnitine transport. Those human studies vary widely in design and quality, and their findings are often inconsistent.

How AOD-9604 acts

AOD-9604 has been reported not to bind the growth hormone receptor with meaningful affinity and not to act through the IGF-1 axis, so its proposed actions differ from those of the whole hormone. Studies in isolated rodent fat cells and in obese mice examined lipolysis and lipogenesis, and some of that work implicated beta-3 adrenergic receptor pathways. A receptor that binds the fragment directly has not been identified. The cartilage studies used animal joint injury models and measured markers of cartilage matrix, and no mechanism for those observations has been established. Overall, the mechanistic literature is small and comes from a limited number of groups.

How L-Carnitine (Levocarnitine) acts

Carnitine's best-characterised role is moving long-chain fatty acids into mitochondria. Carnitine palmitoyltransferase 1 (CPT1), on the outer mitochondrial membrane, transfers the fatty acyl group from coenzyme A to carnitine; carnitine–acylcarnitine translocase carries the acylcarnitine across the inner membrane; and CPT2 on the matrix side converts it back to acyl-CoA for beta-oxidation. CPT1 is inhibited by malonyl-CoA, a control point linking fatty acid and carbohydrate metabolism. Carnitine also accepts surplus acyl groups from coenzyme A, and the acylcarnitines formed can leave the cell, which is why blood acylcarnitine profiles are used in metabolic research and screening.

The records side by side

• Type: AOD-9604, Modified hGH fragment (176-191); L-Carnitine (Levocarnitine), Amino acid derivative (non-peptide)
• Length: AOD-9604, 16 amino acids; L-Carnitine (Levocarnitine), not recorded
• Molecular weight: AOD-9604, 1815.1 g/mol; L-Carnitine (Levocarnitine), 161.20 g/mol
• Molecular formula: AOD-9604, C78H123N23O23S2; L-Carnitine (Levocarnitine), C7H15NO3

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.